At JP Morgan last month, pharmaphorum editor-in-chief Jonah Comstock caught up with Paul Hastings, the CEO of Nkarta, to talk ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Today, adoption of digital health faces some of the same barriers — scepticism, budget limitations, high expectations, and a ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help ...

Martin, who was appointed as Inspector General for the USAID towards the end of 2023 by former President Joe Biden, was ...

As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing. Before the COVID-19 pandemic ...

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

The JP Morgan Healthcare Conference is seen as a barometer for the life sciences industry – and, going into this year’s event, the forecast for the year was particularly grim. At best ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.